Estrazenica stops an expansion of 200 million pounds in Cambridge

3 hours ago

1 minute read

London, September 13 / WAM / The British pharmaceutical giant Estrazenica said it has stopped the expansion of a plan at its research site in Cambridge, with a value of 200 million pounds.

This comes after the pharmaceutical company abandoned plans to invest 450 million pounds in the vaccine factory in Merseyside earlier this year in a blow to the government with its endeavor to emphasize its commitment to developing the economy and making the country more attractive to international investors.

“We are constantly re -evaluating the investment needs of our company and we can confirm our expansion stop in Cambridge,” the British Press Agency, BA Media, quoted a spokesman for Estrazenica as saying on Friday.

He added, “We have no other comment.”

The CEO of Estrazenica Pascal Soreriot said last February that he was “very frustrated” due to the step of canceling the Mercyside website, but indicated that the company “was unable to make the investment to continue economically.”

Last month, Estrazenica announced plans to invest 50 billion dollars in the United States over the next five years, amid an imminent threat from US President Donald Trump to impose commercial fees.

The company said that investment will provide funding for a new manufacturing facility on the latest model “in Virginia, which is scheduled to be the largest investment for the company in manufacturing in the world.